<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04903197</url>
  </required_header>
  <id_info>
    <org_study_id>CVAY736J12101</org_study_id>
    <secondary_id>2020-005881-32</secondary_id>
    <nct_id>NCT04903197</nct_id>
  </id_info>
  <brief_title>Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Phase Ib, Multi-center, Open-label Dose Escalation and Expansion Platform Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma (NHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK),&#xD;
      immunogenicity and preliminary efficacy of VAY736 alone or in combination with other&#xD;
      therapies in patients with NHL in a platform trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to evaluate the safety and tolerability in patients&#xD;
      with NHL and identify a maximum tolerated dose (MTD) and/or recommended dose (RD) of VAY736&#xD;
      single agent and in combination with other anti-cancer therapies.&#xD;
&#xD;
      This is a phase I/Ib, multi-center, open-label study with multiple treatment arms in an&#xD;
      adaptive study design. The study is comprised of a dose escalation part and dose expansion&#xD;
      part.&#xD;
&#xD;
      In dose escalation, the investigational drug VAY736 will be explored alone or in combination&#xD;
      with partner therapies. Increasing doses of VAY736 alone or in combination will be given to&#xD;
      small groups of patients to identify the MTD/RD in patients with NHL. In dose expansion, some&#xD;
      or all the treatments from dose escalation will be tested at the recommended doses in&#xD;
      patients with NHL. The initial combination partner is lenalidomide. Other combination&#xD;
      partners may be added in the future by protocol amendment. The study is expected to be&#xD;
      approximately 4 years in duration (from enrollment of first patient to discontinuation of&#xD;
      last patient).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and nature of dose limiting toxicities (DLTs)</measure>
    <time_frame>28 days (first cycle of treatment)</time_frame>
    <description>Safety and tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>4 years</time_frame>
    <description>Incidence of AEs and SAEs is defined as number of participants with AEs and SAEs, including changes from baseline in vital signs, electrocardiograms (ECGs) and laboratory results qualifying and reported as AEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with dose interruptions and dose reductions</measure>
    <time_frame>4 years</time_frame>
    <description>Safety and tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose intensity</measure>
    <time_frame>4 years</time_frame>
    <description>Safety and tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>4 years</time_frame>
    <description>Efficacy will be assessed by Lugano Classification (FDG-PET/CT scans)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR) rate</measure>
    <time_frame>4 years</time_frame>
    <description>Efficacy will be assessed by Lugano Classification (FDG-PET/CT scans)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under curve (AUC) for VAY736</measure>
    <time_frame>4 years</time_frame>
    <description>PK parameters will be derived from serum concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed drug concentration after single dose administration (Cmax) for VAY736</measure>
    <time_frame>4 years</time_frame>
    <description>PK parameters will be derived from serum concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC for lenalidomide</measure>
    <time_frame>4 years</time_frame>
    <description>PK parameters will be derived from plasma concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for lenalidomide</measure>
    <time_frame>4 years</time_frame>
    <description>PK parameters will be derived from plasma concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in anti-drug antibodies (ADA)</measure>
    <time_frame>Baseline, 4 years</time_frame>
    <description>Blood samples will be collected to detect change in levels of antibodies to VAY736</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm 1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VAY736 single agent dose escalation in patients with diffuse large B cell lymphoma (DLBCL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VAY736 single agent dose expansion in patients with DLBCL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VAY736 + lenalidomide dose escalation in patients with DLBCL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VAY736 + lenalidomide dose expansion in patients with DLBCL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VAY736</intervention_name>
    <description>VAY736 is a fully human IgG1 monoclonal antibody (mAb) which targets the B cell activating factor receptor (BAFF-R) expressed on the surface of differentiated B cells and modulates their function.</description>
    <arm_group_label>Arm 1A</arm_group_label>
    <arm_group_label>Arm 1B</arm_group_label>
    <arm_group_label>Arm 2A</arm_group_label>
    <arm_group_label>Arm 2B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide</intervention_name>
    <description>Immune-modulatory agent that enhances activation of NK cells.</description>
    <arm_group_label>Arm 2A</arm_group_label>
    <arm_group_label>Arm 2B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients with confirmed diagnosis of relapsed/refractory B-cell NHL with all&#xD;
             subtypes of DLBCL, follicular lymphoma (FL), marginal zone lymphoma (MZL) and mantle&#xD;
             cell lymphoma (MCL) per WHO 2016 criteria. Patients in subtype arm e.g. DLBCL must&#xD;
             have confirmed diagnosis of relapsed/refractory DLBCL.&#xD;
&#xD;
          -  Received and failed or be intolerant to standard of care therapy (at least two prior&#xD;
             lines, including an anti-CD20 therapy, but no more than 5 prior lines)&#xD;
&#xD;
          -  Must have measurable disease and ECOG of 0 to 2&#xD;
&#xD;
          -  Must have a site of disease amenable to biopsy and be a candidate for tumor biopsy and&#xD;
             be willing to undergo study required biopsies at screening and during therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Baseline laboratory results outside of protocol defined ranges&#xD;
&#xD;
          -  Presence of history of central nervous system involvement by lymphoma&#xD;
&#xD;
          -  History of hypersensitivity to VAY736 or any drugs in similar chemical classes (e.g.&#xD;
             monoclonal antibodies)&#xD;
&#xD;
          -  Impaired cardiac function or clinically significant cardiac disease&#xD;
&#xD;
          -  History of or current interstitial lung disease or pneumonitis grade 2 or higher&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Active hepatitis C infection and/or hepatitis B infection&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women&#xD;
&#xD;
          -  Women of child-bearing potential unless they are using highly effective methods of&#xD;
             contraception&#xD;
&#xD;
        Other Inclusion/Exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Institutes of Biomedical Research</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Institutes of Biomedical Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koto ku</city>
        <state>Tokyo</state>
        <zip>135 8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Japan</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>May 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VAY736</keyword>
  <keyword>non-Hodgkin lymphoma</keyword>
  <keyword>NHL</keyword>
  <keyword>DLBCL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

